Lateef Mohiuddin Khan1. 1. Department of Pharmacology, Faculty of Medicine, King Abdulaziz University, P.O. Box 80205, Jeddah, 21589, Saudi Arabia, lmkhan00@hotmail.com.
Abstract
PURPOSE: To study and analyze the comparative impact of hospital-acquired adverse drug reactions (ADRs) in adult and pediatric patients in terms of the economic implications, (length of) hospital stay, and salient features in relation to the incidence rate, severity, morbidity, mortality, and preventability of the ADRs. METHODS: A systematic search to identify and retrieve relevant articles/studies in the PubMed, Medline, Scopus, MEDPAR, and Cochrane databases and by the Google search engine was performed for the study period 2000 to April 2013. In total, 51 studies were identified on patients hospitalized for ADRs, and these were included in the study. The incidence rate of ADRs, their severity, mortality, morbidity, preventability, cost, and association with extended hospital stay due to ADRs were extracted and scrutinized. RESULTS: Hospital-acquired ADRs are more widely studied in adults than in children, and the incidence rate is higher in the former. However, a wide variation in the incidence rate worldwide is observed in both groups. Irrespective of the ages of patients, ADRs are among the most frequent causes of morbidity and mortality. Interestingly, preventable ADRs are more frequently observed in patients at the younger and older ends of the age spectrum. Hospital-acquired ADRs place an immense economic burden on healthcare systems, with the overall cost for a hospitalized patient with an ADR reported to be $2,401 per patient, which is equivalent to a 19.86 % additional increase in the total cost of care and an increase in average length of hospital stay of 8.25 %. CONCLUSION: Based on the findings of this review, we suggest that excellent assertive measures of pharmacovigilance with the aim to diminish the incidence rate of hospital-acquired ADRs and support the development of interventions are needed to promote vital facets of drug safety with an overall objective to avert potential ADRs.
PURPOSE: To study and analyze the comparative impact of hospital-acquired adverse drug reactions (ADRs) in adult and pediatric patients in terms of the economic implications, (length of) hospital stay, and salient features in relation to the incidence rate, severity, morbidity, mortality, and preventability of the ADRs. METHODS: A systematic search to identify and retrieve relevant articles/studies in the PubMed, Medline, Scopus, MEDPAR, and Cochrane databases and by the Google search engine was performed for the study period 2000 to April 2013. In total, 51 studies were identified on patients hospitalized for ADRs, and these were included in the study. The incidence rate of ADRs, their severity, mortality, morbidity, preventability, cost, and association with extended hospital stay due to ADRs were extracted and scrutinized. RESULTS: Hospital-acquired ADRs are more widely studied in adults than in children, and the incidence rate is higher in the former. However, a wide variation in the incidence rate worldwide is observed in both groups. Irrespective of the ages of patients, ADRs are among the most frequent causes of morbidity and mortality. Interestingly, preventable ADRs are more frequently observed in patients at the younger and older ends of the age spectrum. Hospital-acquired ADRs place an immense economic burden on healthcare systems, with the overall cost for a hospitalized patient with an ADR reported to be $2,401 per patient, which is equivalent to a 19.86 % additional increase in the total cost of care and an increase in average length of hospital stay of 8.25 %. CONCLUSION: Based on the findings of this review, we suggest that excellent assertive measures of pharmacovigilance with the aim to diminish the incidence rate of hospital-acquired ADRs and support the development of interventions are needed to promote vital facets of drug safety with an overall objective to avert potential ADRs.
Authors: B J Paessens; C von Schilling; K Berger; M Shlaen; C Müller-Thomas; R Bernard; C Peschel; A Ihbe-Heffinger Journal: Ann Oncol Date: 2011-02-22 Impact factor: 32.976
Authors: Emma C Davies; Christopher F Green; Stephen Taylor; Paula R Williamson; David R Mottram; Munir Pirmohamed Journal: PLoS One Date: 2009-02-11 Impact factor: 3.240
Authors: Alfredo José Pardo Cabello; Esperanza Del Pozo Gavilán; Francisco Javier Gómez Jiménez; Carmen Mota Rodríguez; Juan de Dios Luna Del Castillo; Emilio Puche Cañas Journal: Eur J Clin Pharmacol Date: 2016-02-20 Impact factor: 2.953
Authors: Amanda Lavan; Joseph Eustace; Darren Dahly; Evelyn Flanagan; Paul Gallagher; Shane Cullinane; Mirko Petrovic; Katrina Perehudoff; Adalsteinn Gudmondsson; Ólafur Samuelsson; Ástrós Sverrisdóttir; Antonio Cherubin; Frederica Dimitri; Joe Rimland; Alfonso Cruz-Jentoft; Manuel Vélez-Díaz-Pallarés; Isabel Lozano Montoya; Roy L Soiza; Selvarani Subbarayan; Denis O'Mahony Journal: Ther Adv Drug Saf Date: 2017-10-24
Authors: Lateef M Khan; Sameer E Al-Harthi; Huda M Alkreathy; Abdel-Moneim M Osman; Ahmed S Ali Journal: Saudi Pharm J Date: 2014-10-31 Impact factor: 4.330